Acquisition (action) – Page 4

RNA Startup ReNAgade Acquired by Competitor Following Mega-Round Funding

11 months ago talkbio0Tagged Acquisition (action), launch, mega-round, ReNAgade, RNA, startup

ReNAgade, RNA, startup, acquisition, competitor, mega-round funding, launch

Biogen Expands Immunology Portfolio with $1.15 Billion Acquisition of HI-Bio

11 months ago talkbio0Tagged Acquisition (action), Biogen, Drug Development, expansion, HI-Bio, Immunology

Biogen, HI-Bio, acquisition, immunology, $1.15 billion, expansion, therapeutics, drug development

AstraZeneca Acquires Option for SixPeaks: A Potential Breakthrough in Obesity Biotechnology

11 months ago talkbio0Tagged Acquisition (action), AstraZeneca, Biotechnology, Obesity, SixPeaks, Ventures, Versant

AstraZeneca, SixPeaks, Versant Ventures, obesity, biotechnology, acquisition, option, breakthrough.

Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition

11 months ago talkbio0Tagged Acquisition (action), Aktis, Cancer Therapeutic Procedure, cellular targeting, Eli Lilly, portfolio, Radiopharmaceuticals

Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment

Johnson & Johnson Expands Dermatology Portfolio with $850M Acquisition of Proteologix

11 months ago talkbio0Tagged Acquisition (action), bispecifics, Dermatitis, Atopic, J&J, Johnson and Johnson, Proteologix

Johnson & Johnson, J&J, Proteologix, atopic dermatitis, bispecifics, pipeline, acquisition, $850M

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

11 months ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics

12 months ago talkbio0Tagged Acquisition (action), CDK-like kinase inhibitors, Collaboration, development aspects, Epygenix, genetic epilepsies, Harmony Pharmaceuticals, Infantile Severe Myoclonic Epilepsy, Mutation, research

Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

12 months ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.

Lilly Acquires Injectable Medicines Production Facility from Nexus Pharma

12 months ago talkbio0Tagged Acquisition (action), Capacity, Eli Lilly, expansion, Facility (object), Injectables, Nexus Pharma, pharmaceutical manufacturing, production, strategic

Lilly, Nexus Pharma, injectable medicines, facility acquisition, pharmaceutical manufacturing, strategic expansion, production capacity.

Strategic Acquisition, Partnership, and Development of Innovative Assets in Biopharma

12 months ago talkbio0Tagged Acquisition (action), Biopharma, development aspects, Drug Development, Drug Industry, innovative assets, Market, Partnership, Portfolio diversification, Risk Management, strategic decision-making, trends qualifier

Biopharma, Innovative Assets, Acquisition, Partnership, Development, Strategic Decision-Making, Pharmaceutical Industry, Drug Development, Market Trends, Risk Management, Portfolio Diversification